Prevalence, risk factors, and diagnosis of comorbidity of chronic obstructive pulmonary disease and cardiovascular disease
DOI: https://doi.org/10.29296/25877305-2020-09-05
Issue:
9
Year:
2020
At present, doctors with various medical specialties are often found with comorbidity (a
combination of several diseases in the same patient). An important place among them is occupied by the
problem of the combination of chronic obstructive pulmonary disease and cardiovascular diseases, due to the
fact that these diseases affect the vital systems of the body, are widespread, have almost the same risk
factors for occurrence, and there is still no consensus on the optimal diagnosis and treatment of such
patients. This article presents current data on the prevalence, risk factors, pathogenesis and diagnosis of
comorbidity of chronic obstructive pulmonary disease and cardiovascular disease.
Keywords:
cardiology
pulmonology
chronic obstructive pulmonary disease
cardiovascular disease
heart failure
myocardial infarction
stroke
risk factors
diagnosis
References:
- Feinstein A.R. The pre-therapeutic classification of comorbidity in chronic disease. J Chronic Dis. 1970; 23 (7): 455–68. DOI: 10.1016/0021-9681(70)90054-8
- Vertkin A.L. Komorbidnost': istorija, sovremennoe predstavlenie, profilaktika i lechenie. Kardiovaskuljarnaja terapija i profilaktika. 2015; 14 (2): 74–9 [Vertkin A.L. Comorbidity: history, recent views, prevention and treatment. Cardiovascular Therapy and Prevention. 2015; 14 (2): 74–9 (in Russ.)]. https://doi.org/10.15829/1728-8800-2015-2-74-79
- Charlson M.E., Pompei P., Ales K.L. et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987; 40 (5): 373–83. DOI: 10.1016/0021-9681(87)90171-8
- Tarlovskaja E.I. Komorbidnost' i polimorbidnost' – sovremennaja traktovka i nasuschnye zadachi, stojaschie pered terapevticheskim soobschestvom. Kardiologija. 2018; 58 (S9): 29–38 [Tarlovskaya E.I. Comorbidity and polymorbidity – a modern interpretation and urgent tasks facing the therapeutic community. Kardiologiia. 2018; 58 (9S): 29–38 (in Russ.)]. DOI: 10.18087/cardio.2562
- Adeloye D., Chua S., Lee C. et al. Global and regional estimates of COPD prevalence: Systematic review and meta-analysis. J Glob Health. 2015; 5 (2): 020415. DOI: 10.7189/jogh.05-020415
- Public Health England. Public Health Profiles: Inhale – INteractive Health Atlas of Lung conditions in England. London: Public Health England. URL: http://fingertips.phe.org.uk/
- GBD 2015 Chronic Respiratory Disease Collaborators. Global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Respir Med. 2017; 5 (9): 691–706. DOI: 10.1016/S2213-2600(17)30293-X
- Divo M., Cote C., de Torres J.P. et al. Comorbidities and risk of mortality in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2012; 186 (2): 155–61. DOI: 10.1164/rccm.201201-0034OC
- Chen W., Thomas J., Sadatsafavi M. et al. Risk of cardiovascular comorbidity in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. Lancet Respir Med. 2015; 3 (8): 631–9. DOI: 10.1016/S2213-2600(15)00241-6
- Cazzola M., Rogliani P., Matera M.G. Cardiovascular disease in patients with COPD. Lancet Respir Med. 2015; 3 (8): 593–5. DOI: 10.1016/S2213-2600(15)00279-9
- Roversi S., Fabbri L.M., Sin D.D. et al. Chronic Obstructive Pulmonary Disease and Cardiac Diseases. An Urgent Need for Integrated Care. Am J Respir Crit Care Med. 2016; 194 (11): 1319–36. DOI: 10.1164/rccm.201604-0690SO
- Mullerova H., Agusti A., Erqou S. et al. Cardiovascular comorbidity in COPD: systematic literature review. Chest. 2013; 144 (4): 1163–78. DOI: 10.1378/chest.12-2847
- Grigor'eva N.Ju., Majorova M.V., Koroleva M.E. i dr. Osobennosti formirovanija i razvitija serdechno-sosudistyh zabolevanij u bol'nyh hronicheskoj obstruktivnoj bolezn'ju legkih. Ter arh. 2019; 91 (1): 16–47 [Grigoryeva N.Yu., Maiorova M.V., Korolyova M.E. et al. Somorbidity and polymorbidity of the patient with chronic obstructive pulmonary disease and cardiovascular diseases. Therapeutic Archive. 2019; 91 (1): 16–47 (in Russ.)]. DOI: 10.26442/00403660.2019.01.000027
- Lahousse L., Tiemeier H., Ikram M.A. et al. Chronic obstructive pulmonary disease and cerebrovascular disease: A comprehensive review. Respir Med. 2015; 109 (11): 1371–80. DOI: 10.1016/j.rmed.2015.07.014
- Morgan A.D., Sharma C., Rothnie K.J et al. Chronic Obstructive Pulmonary Disease and the Risk of Stroke. Ann Am Thorac Soc. 2017; 14 (5): 754–65. DOI: 10.1513/AnnalsATS.201611-932SR
- Houben-Wilke S., Jorres R.A, Bals R. et al. Peripheral Artery Disease and Its Clinical Relevance in Patients with Chronic Obstructive Pulmonary Disease in the COPD and Systemic Consequences-Comorbidities Network Study. Am J Respir Crit Care Med. 2017; 195 (2): 189–97. DOI: 10.1164/rccm.201602-0354OC
- Brusselle G., Bracke K., De Pauw M. Peripheral Artery Disease in Patients with Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med. 2017; 195 (2): 148–50. DOI: 10.1164/rccm.201608-1712ED
- Decramer M., Janssens W. Chronic obstructive pulmonary disease and comorbidities. Lancet Respir Med. 2013; 1 (1): 73–83. DOI: 10.1016/S2213-2600(12)70060-7
- Maclay J.D., MacNee W. Cardiovascular disease in COPD: mechanisms. Chest. 2013; 143 (3): 798–807. DOI: 10.1378/chest.12-0938
- Fabbri L.M. Smoking, Not COPD, as the Disease. N Engl J Med. 2016; 374 (19): 1885–6. DOI: 10.1056/NEJMe1515508
- Rabe K.F., Watz H. Chronic obstructive pulmonary disease. Lancet. 2017; 389 (10082): 1931–40. DOI: 10.1016/S0140-6736(17)31222-9
- Belenkov Ju.N., Tsvetkova O.A., Privalova E.V. i dr. Komorbidnost' hronicheskoj obstruktivnoj bolezni legkih i serdechno-sosudistyh zabolevanij: mesto terapii sovremennymi β-adrenoblokatorami. Kardiologija. 2019; 59 (6): 48–55 [Belenkov Y.N., Tsvetkova O.A., Privalova E.V. et al. Comorbidity of Chronic Obstructive Pulmonary Disease and Cardiovascular Diseases: Place of Therapy with Modern β-Adrenoblockers. Kardiologiia. 2019; 59 (6): 48–55 (in Russ.)]. https://doi.org/10.18087/cardio.2019.6.n458
- Agafonova O.V., Gritsenko T.A., Bogdanova Ju.V. i dr. Poliklinicheskaja terapija: Uchebnik. Pod red. D.I. Davydkina, Ju.V. Schukina. 2-e izd., pererab. i dop. M.: GEOTAR-Media, 2020; 840 s. [Agafonova O.V., Gritsenko T.A., Bogdanova Yu.V. i dr. Poliklinicheskaya terapiya: Uchebnik. Pod red. D.I. Davydkina, Yu.V. Shchukina. 2-e izd., pererab. i dop. M.: GEOTAR-Media, 2020; 840 s. (in Russ.)]. DOI: 10.33029/9704-5545-6-PLT-2020-1-840
- Violan C., Foguet-Boreu Q., Flores-Mateo G. et al. Prevalence, determinants and patterns of multimorbidity in primary care: a systematic review of observational studies. PLoS One. 2014; 9 (7): e102149. DOI: 10.1371/journal.pone.0102149
- Barnes P.J. Senescence in COPD and Its Comorbidities. Annu Rev Physiol. 2017; 79: 517–39. DOI: 10.1146/annurev-physiol-022516-034314
- Savale L., Chaouat A., Bastuji-Garin S. et al. Shortened telomeres in circulating leukocytes of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2009; 179 (7): 566–71. DOI: 10.1164/rccm.200809-1398OC
- Tsuji T., Aoshiba K., Nagai A. Alveolar cell senescence in patients with pulmonary emphysema. Am J Respir Crit Care Med. 2006; 174 (8): 886–93. DOI: 10.1164/rccm.200509-1374OC
- Benetos A., Okuda K., Lajemi M. et al. Telomere length as an indicator of biological aging: the gender effect and relation with pulse pressure and pulse wave velocity. Hypertension. 2001; 37 (2 Pt 2): 381–5. DOI: 10.1161/01.hyp.37.2.381
- Maclay J.D., McAllister D.A., Rabinovich R. et al. Systemic elastin degradation in chronic obstructive pulmonary disease. Thorax. 2012; 67 (7): 606–12. DOI: 10.1136/thoraxjnl-2011-200949
- Austin V., Crack P.J., Bozinovski S. et al. COPD and stroke: are systemic inflammation and oxidative stress the missing links? Clin Sci (Lond). 2016; 130 (13): 1039–50. DOI: 10.1042/CS20160043
- Kida Y., Goligorsky M.S. Sirtuins, Cell Senescence, and Vascular Aging. Can J Cardiol. 2016; 32 (5): 634–41. DOI: 10.1016/j.cjca.2015.11.022
- Libby P., Ridker P.M., Maseri A. Inflammation and atherosclerosis. Circulation. 2002; 105 (9): 1135–43. DOI: 10.1161/hc0902.104353
- Gan W.Q., Man S.F., Senthilselvan A. et al. Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. Thorax. 2004; 59 (7): 574–80. DOI: 10.1136/thx.2003.019588
- de Torres J.P., Cordoba-Lanus E., Lopez-Aguilar C. et al. C-reactive protein levels and clinically important predictive outcomes in stable COPD patients. Eur Respir J. 2006; 27 (5): 902–7. DOI: 10.1183/09031936.06.00109605
- Hurst J.R., Donaldson G.C., Perera W.R. et al. Use of plasma biomarkers at exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2006; 174 (8): 867–74. DOI: 10.1164/rccm.200604-506OC
- Roversi S., Roversi P., Spadafora G. et al. Coronary artery disease concomitant with chronic obstructive pulmonary disease. Eur J Clin Invest. 2014; 44 (1): 93–102. DOI: 10.1111/eci.12181
- Celli B.R., Locantore N., Yates J. et al. Inflammatory biomarkers improve clinical prediction of mortality in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2012; 185 (10): 1065–72. DOI: 10.1164/rccm.201110-1792OC
- Marchetti N., Ciccolella D.E., Jacobs M.R. et al. Hospitalized acute exacerbation of COPD impairs flow and nitroglycerin-mediated peripheral vascular dilation. COPD. 2011; 8 (2): 60–5. DOI: 10.3109/15412555.2011.558541
- Seidel D., Cheung A., Suh E.S. et al. Physical inactivity and risk of hospitalisation for chronic obstructive pulmonary disease. Int J Tuberc Lung Dis. 2012; 16 (8): 1015–9. DOI: 10.5588/ijtld.12.0050
- Cohen A.J., Brauer M., Burnett R. et al. Estimates and 25-year trends of the global burden of disease attributable to ambient air pollution: an analysis of data from the Global Burden of Diseases Study 2015. Lancet. 2017; 389 (10082): 1907–18. DOI: 10.1016/S0140-6736(17)30505-6
- Wright J.L., Petty T., Thurlbeck W.M. Analysis of the structure of the muscular pulmonary arteries in patients with pulmonary hypertension and COPD: National Institutes of Health nocturnal oxygen therapy trial. Lung. 1992; 170 (2): 109–24. DOI: 10.1007/bf00175982
- Dinh-Xuan A.T., Higenbottam T.W., Clelland C.A. et al. Impairment of endothelium-dependent pulmonary-artery relaxation in chronic obstructive lung disease. N Engl J Med. 1991; 324 (22): 1539–47. DOI: 10.1056/NEJM199105303242203
- Chaudary N., Geraci S.A. Prognostic value of cardiac-specific troponins in chronic obstructive pulmonary disease exacerbations: a systematic review. J Miss State Med Assoc. 2014; 55 (2): 40–4. URL: https://www.ncbi.nlm.nih.gov/pubmed/25771612
- Chaulin A.M., Karsljan L.S., Grigor'eva E.V. i dr. Kliniko-diagnosticheskaja tsennost' kardiomarkerov v biologicheskih zhidkostjah cheloveka. Kardiologija. 2019; 59 (11): 66–75 [Chaulin A.M., Karslyan L.S., Bazyuk E.V. et al. Clinical and Diagnostic Value of Cardiac Markers in Human Biological Fluids. Kardiologiia. 2019; 59 (11): 66–75 (in Russ.)]. https://doi.org/10.18087/cardio.2019.11.n414
- Chaulin A.M., Karsljan L.S., Grigor'eva E.V. i dr. Osobennosti metabolizma serdechnyh troponinov (obzor literatury). Kompleksnye problemy serdechno-sosudistyh zabolevanij. 2019; 8 (4): 103–15 [Chaulin A.M., Karslyan L.S., Grigorieva E.V. et al. Metabolism of cardiac troponins (literature review). Complex Issues of Cardiovascular Diseases. 2019; 8 (4): 103–15 (in Russ.)]. https://doi.org/10.17802/2306-1278-2019-8-4-103-115
- Chaulin A.M., Karsljan L.S., Dupljakov D.V. Nekoronarogennye prichiny povyshenija troponinov v klinicheskoj praktike. Klinicheskaja praktika. 2019; 10 (4): 81–93 [Chaulin A.M., Karslyan L.S., Duplyakov D.V. Non-coronarogenic causes of increased cardiac troponins in clinical practice. Journal of Clinical Practice. 2019; 10 (4): 81–93 (in Russ.)]. https://doi.org/10.17816/clinpract16309
- Chaulin A.M., Dupljakov D.V. Povyshenie kardial'nyh troponinov, ne assotsiirovannoe s ostrym koronarnym sindromom. Chast' 1. Kardiologija: novosti, mnenija, obuchenie. 2019; 7 (2): 13–23 [Chaulin A.M., Duplyakov D.V. Increased cardiac troponins, not associated with acute coronary syndrome. Part 1. Kardiologiya: novosti, mneniya, obuchenie = Cardiology: News, Opinions, Training. 2019; 7 (2): 13–23 (in Russ.)]. DOI: 10.24411/2309-1908-2019-12002
- Lahousse L., Verhamme K.M., Stricker B.H. et al. Cardiac effects of current treatments of chronic obstructive pulmonary disease. Lancet Respir Med. 2016; 4 (2): 149–64. DOI: 10.1016/S2213-2600(15)00518-4
- Gershon A., Croxford R., Calzavara A. et al. Cardiovascular safety of inhaled long-acting bronchodilators in individuals with chronic obstructive pulmonary disease. JAMA Intern Med. 2013; 173 (13): 1175–85. DOI: 10.1001/jamainternmed.2013.1016
- Rothnie K.J., Smeeth L., Herrett E. et al. Closing the mortality gap after a myocardial infarction in people with and without chronic obstructive pulmonary disease. Heart. 2015; 101 (14): 1103–10. DOI: 10.1136/heartjnl-2014-307251
- Lipworth B., Wedzicha J., Devereux G. et al. Beta-blockers in COPD: time for reappraisal. Eur Respir J. 2016; 48 (3): 880–8. DOI: 10.1183/13993003.01847-2015
- Vanfleteren L.E., Spruit M.A., Wouters E.F. et al. Management of chronic obstructive pulmonary disease beyond the lungs. Lancet Respir Med. 2016; 4 (11): 911–24. DOI: 10.1016/S2213-2600(16)00097-7
- MacDonald M.I., Shafuddin E., King P.T. et al. Cardiac dysfunction during exacerbations of chronic obstructive pulmonary disease. Lancet Respir Med. 2016; 4 (2): 138–48. DOI: 10.1016/S2213-2600(15)00509-3